 |
|
|
| |
SAFETY, EFFICACY, AND DURABILITY OF LONG-ACTING CABOTEGRAVIR AND RILPIVIRINE AS MAINTENANCE THERAPY
FOR HIV-1 INFECTION: LATTE-2 WEEK 256 RESULTS
|
| |
| |
IDWeek 2020 Oct 21-25 virtual
Reported by Jules Levin
Graham Smith1, Keith Henry2, Daniel Podzamczer3, Mar Masiá4, Christopher Bettacchi5, Keikawus Arasteh6, Hans Jaeger7, Marie-Aude Khuong-Josses8, Kenneth Sutton9, Feifan Zhang10, Cynthia McCoig11, Kati Vandermeulen12, Rodica Van Solingen-Ristea12, William R. Spreen9, David A. Margolis9
1Maple Leaf Research, Toronto, ON, Canada; 2Hennepin County Medical Center, Minneapolis, MN, United States; 3Hospital Universitari de Bellvitge, L'Hospitalet, Barcelona, Spain; 4Hospital General Universitario de Elche, Elche, Spain; 5North Texas Infectious Disease Consultants, Dallas, TX, United States; 6Epimed GmbH, Berlin, Germany;
7MUC Research GmbH, Munich, Germany; 8Service Maladies Infectieuses, CHG - Hôpital Delafontaine, Saint Denis, France; 9ViiV Healthcare, Research Triangle Park, NC, United States; 10GlaxoSmithKline, Collegeville, PA, United States; 11ViiV Healthcare, Tres Cantos, Spain; 12Janssen Research and Development, Beerse, Belgium
|
| |
|
|
|
|
|
